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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Mannitol is commonly used in patients with increased intracranial pres-
sure (ICP), but its effect on cerebrovascular pressure reactivity (CVPR) is uncertain.We analyzed
the changes of pressure reactivity index (PRx) during the course of mannitol treatment.
Methods: Twenty-one patients who received mannitol treatment for increased ICP were re-
cruited prospectively. Continuous waveforms of arterial blood pressure (ABP) and ICP were
collected simultaneously for 60 minutes (10 minutes at baseline and 50 minutes since mannitol
administration) during 37 events of mannitol treatment. The correlation coefficients between
the mean ABP and ICP were averaged every 10 minutes and labeled as the PRx. The linear corre-
lation of six time points of PRx in each event was calculated to represent the trend of CVPR
changes. The negative slope of correlation was defined as improvement in CVPR under mannitol
treatment and vice versa.
Results: At baseline, the average of ICP was 26.0 9.1 mmHg and the values of PRx were signif-
icantly correlatedwith ICP (pZ 0.0044, rZ 0.46). Aftermannitol administration, the average of
ICP decreased significantly to 21.2 11.1 mmHg (pZ 0.036), and CVPR improved in 59.4 % of all
events. Further analysis showed that low baseline cerebral perfusion pressure was the onlyhave no conflicts of interest relevant to this article.
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Mannitol and CVPR in ICP patients 843hemodynamic parameter significant association with the improvement of CVPR after mannitol
treatment (pZ 0.039).
Conclusion: Despite lowering ICP, mannitol may have diverse effects on CVPR in patients with
intracranial hypertension. Our study suggests thatmannitol infusionmay have a beneficial effect
on CVPR, particularly in those with a low cerebral perfusion pressure at baseline.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Elevated intracranial pressure (ICP) has longbeen recognized
as a serious complication in neurocritical diseases, including
traumatic brain injury (TBI), acute stroke, central nervous
system infections, and intracranial neoplasms.1e5 Among the
many strategies for lowering ICP, intravenousmannitol is the
most widely used solute for the treatment of brain edema
due to increased ICP.6 Its effect in lowering ICP usually starts
in few minutes after initiation of mannitol administration
with a peak effect at 20e60 minutes.6 Previous studies have
demonstrated the effect of mannitol in lowering ICP,7e9 but
the underlying mechanisms remain a matter of debate.
Possible theories include decreasing cerebral volume due to
extracting water from the brain tissue, a fall in cerebral
blood flow due to cerebral vasoconstriction from increasing
blood pressure, and a decrease of serum viscosity.6,10e13
Recently, one study used an intraparenchyma microdialysis
method and demonstrated a significant decrease of lacta-
teepyruvate ratio, which indicated an improvement of
intracranial metabolism following mannitol treatment in
patients with severe hemorrhagic stroke.14 However,
lowering ICP via the use of mannitol in patients with
increased ICP did not refer to an overall beneficial effect on
functional outcome in various neurological diseases.6,15,16
Cerebrovascular pressure reactivity (CVPR) is the ability
of cerebral vessels to respond to changes in transmural
pressure, which indicates that cerebral arterioles would
constrict in response to an increase in cerebral perfusion,
and vice versa.17 CVPR represents a key element of cere-
bral autoregulation (CA) and the status of CVPR has been
shown to be critical in maintaining proper cerebral blood
flow and global oxygenation.17,18 The pressure reactivity
index (PRx), which is determined as the moving correlation
coefficient between ICP and arterial blood pressure (ABP),
can quantify the status of CVPR.19e24 In patients with TBI or
severe stroke, several studies have shown that the values of
PRx were correlated with the levels of ICP, and were also
found to be an independent predictor of outcome.19e23
However, whether lowering ICP via mannitol administra-
tion confers some improvement on CVPR is uncertain. The
aim of our study was to investigate the effect of mannitol
on CVPR by analyzing the sequential change in PRx through
a 1-hour course of mannitol treatment.Methods
Study participants
Twenty-one patients (mean age: 47.7  21.2 years; male:
57.1 %) receiving ICP monitoring and intravenous bolus ofmannitol treatment due to increased ICP (15 mmHg) in
the stroke and neurosurgical intensive care units of Na-
tional Taiwan University were prospectively recruited. The
etiologies of the study participants included TBI (n Z 8),
acute stroke (n Z 10), and brain tumor (n Z 3).
Patients were excluded if they were younger than 18
years, pregnant, or had concomitant use of other osmotic
agent such as glycerol or hypertonic saline. All patients
were artificially ventilated to prevent hypoxia and hyper-
capnia. This study involved observational data collection
and did not interfere with the management and clinical
decision-making of the intensivists. This study was
approved by the Research Ethics Committee, National
Taiwan University Hospital and was conducted in accor-
dance with human ethics regulations.Management of increased ICP
A standard treatment approach was used for the manage-
ment of increased ICP.17 The therapeutic targets were
adjusted to maintain ICP  15 mmHg or cerebral perfusion
pressure (CPP)  60 mmHg. The standard protocol included
elevating the head of the bed by 15e30, administering
sedation (lorazepam) or analgesia (fentanyl) if patients
were agitated, and intermittent drainage of cerebrospinal
fluid if an external ventricular drain was in place.1,14,15 ABP
was continuously measured using a radial artery fluid-
coupled system. ICP was monitored using flexible intra-
parenchymal probes (Codman Microsensors ICP Transducer;
Codman and Shurtleff, Raynham, MA, USA; and Licox
CCI.SB; Integra NeuroSciences, Plainsboro, NJ, USA,
respectively) inserted via a double-lumen skull bolt kit
(Licox IM2; Integra Neuro-Sciences). For patients with ICP 
15 mmHg for > 5 minutes, intermittent intravenous bolus of
20% mannitol 150 mL (approximately 0.5 g/kg) was infused
over 20 minutes every 6e8 hours.Data collection and analysis
Continuous waveforms of ABP and ICP were collected
simultaneously for a mean duration of 60 minutes
(60.3  5.4 minutes), starting from 10 minutes prior to
mannitol administration. Data was not collected if the pa-
tients were undergoing routine nursing or rehabilitation
activities during the 1-hour course of mannitol treatment.
These two waveforms (ABP and ICP) were captured digi-
tally, with a sampling rate of 100 Hz, using a data acquisi-
tion card (National Instruments, Austin, TX, USA) on a
bedside laptop computer. Artifacts were identified and
excluded from analysis after data collection was
completed. The software for this data collection was
844 S.-C. Tang et al.designed by the authors, and it has been patented (Patent
No. I 256572) in Taiwan.
Data from the continuous waveforms of ABP and ICP
were averaged for every 1-minute period to get the mean
ABP and ICP over the whole monitoring period. CPP was
calculated as the mean ABP minus ICP. The method of
obtaining PRx was as previous described.18e22 In brief, the
values of ABP and ICP in the time domains were averaged
for 3-second periods offline. From every 20 such values
(i.e., 60-second periods), separate Pearson product-
moment correlation coefficients between the mean ABP
and ICP were calculated. The resulting sets of 1-minute
correlation coefficients were then averaged every 10 mi-
nutes, and labeled as the PRx, representation the status of
CVPR during that 10 minute period.18e20
According to previous literature,18e22 a positive PRx
signifies a positive association between the slow compo-
nents of ABP and ICP, indicating a passive behavior of the
vascular bed, and cerebral blood volume will increase or
decrease passively (in the same direction) in response to
changes in ABP. A negative value of PRx reflects an active
reactive vascular bed, with ABP waves provoking inversely
correlated waves in ICP. Because the correlation coefficient
has a standardized value (range, 1 to þ1), the PRx can be
presented and analyzed as a time-dependent variable,
responding to some dynamic events such as ICP changes or
incidents of arterial hypo- and hypertension.18e22
Statistical analysis
The PRx and other parameters prior to (baseline) and after
mannitol administration were averaged every 10 minutes;
thus, each event had the six time points of data (PRx, ICP,
ABP, and CPP). To quantitatively analyze the trend of PRx
changes during the 1-hour course of mannitol treatment in
each event, linear correlation of six time points of PRx was
performed. We defined the negative slope of the correla-
tion analysis as improved CVPR after mannitol administra-
tion (meaning the trend of gradual decrease in PRx) and
positive slope as deteriorated CVPR (meaning the trend of
gradual increase in PRx). A univariate paired t test was used
to compare the differences in all parameters between
baseline and after treatment. Linear correlation analysis
was used to compare the association between various he-
modynamic parameters and PRx slopes. For all analyses, p
 0.05 was considered to be statistically significant.
Results
Table 1 lists the demographic data of the participants and
baseline mean ABP, ICP, and PRx in each event. The aver-
ages of admission Glasgow Coma Scale at admission and
length of stay in hospital were 10.6  3.7 days and
62.6  45.8 days, respectively. Three patients died during
the course of hospitalization (14.3%).
A total of 37 events of increased ICP treated with
mannitol with 1 hour’s data recording were analyzed. The
number of events analyzed/patient was one in nine pa-
tients, two in eight patients, and three in four patients (16
events from stroke, 14 from TBI, and 7 from brain tumor
patients). Prior to mannitol administration, the averagebaseline ICP was 26.0  9.1 mmHg; CPP, 83.5  23.0 mmHg;
and mean ABP, 109.5  24.2 mmHg and PRx, 0.31  0.39.
There was a significant correlation between baseline PRx
and ICP (p Z 0.0044, r Z 0.46; Fig. 1).
Table 2 summarizes the effect of mannitol administra-
tion on the measured variables. As compared with the
baseline parameters, there was a significant reduction in
ICP to 21.2  11.1 mmHg (p Z 0.036), occurring at an
average of 34.4  12.4 minutes after the administration of
mannitol. However, the changes of averaged PRx in all
events were not obvious during the 1-hour course of
mannitol treatment, as shown in Fig. 2A. Further analysis
revealed that the response of CVPR to mannitol treatment
among collected data was diverse: CVPR improved (slope of
PRx < 0) in 22 events (59.4%) but worsened (slope of PRx >
0) in the other 15 events. Fig. 2B and C demonstrate two
different responses of PRx changes after mannitol admin-
istration despite both events had ICP lowering during the
course of treatment.
Importantly, events with improvement of CVPR (PRx
slope < 0) had a significantly lower baseline CPP
(77.1  19.6 versus 92.9  25.1 mmHg, p Z 0.039), as
compared to those with a poor response (PRx slope > 0),
but no difference in baseline BP, ICP, and PRx. The effect of
baseline CPP on CVPR remained significant after adjust-
ment of baseline BP and ICP (p Z 0.05). Furthermore, the
value of the slope was significantly positively correlated
with baseline CPP (p Z 0.0093, r Z 0.42) but not with
baseline BP or ICP, which indicates that improvements in
CVPR after mannitol administration are more likely to
happen in those with an initial lower CPP. Subgroup analysis
showed no significant difference among basic profiles (age,
sex, baseline ABP, ICP, CPP, and PRx), percentage of ICP
lowering and slopes of PRx between TBI and stroke
patients.
In consideration of the factor that multiple measure-
ments in each patient might possibly outweigh the results,
we chose the first recording event of each patient for
similar assay (n Z 21). The value of the slope was still
significantly positively correlated with baseline CPP
(p Z 0.034, r Z 0.47). However, the difference of CPP
between events with improvement or nonimprovement of
CVPR was not statistically significant (80.2  17.6 vs.
93.4  28.9, p Z 0.199), possibly related to small sample
size.Discussion
Nowadays, effective control of elevated ICP remains a
major issue in neurointensive care.1,16,25 Although hyper-
ventilation, sedation, metabolic suppression, hypothermia,
and surgery have important roles in the management of
increased ICP, osmotherapy including mannitol or hyper-
tonic saline is still the mainstay of recommended treatment
in clinical practice.6 However, there remain some cases in
which mannitol is ineffective in controlling intracranial
hypertension, and accumulation of mannitol in injured tis-
sue may even lead to paradoxical rebound cerebral
edema.26e28 Mannitol also has some undesirable systemic
complications, such as acute renal failure, hypotension, or
hypovolemia.6,29
Table 1 Clinical demographic data of the 21 patients.
Etiology Patient Sex Age Presentation Initial
GCS
Preop
GCS
Outcome
(GOS)
Operation MABP
(mmHg)
ICP
(mmHg)
PRx
Traumatic brain injury (TBI)
TBI-1 M 31 SDH, SAH 13 13 5 Craniectomy 89 19 0.25
100 20 0.36
117 28 0.61
TBI-2 M 65 SDH 7 7 2 Craniectomy 100 31 0.50
TBI-3 M 45 SDH, EDH, SAH 11 9 Craniectomy 115 24 0.54
TBI-4 M 45 SDH, EDH 7 7 1 Craniectomy 103 44 0.97
TBI-5 M 54 EDH 15 4 5 Craniectomy 106 17 0.41
TBI-6 F 19 SDH, EDH SAH 4 4 2 Craniectomy 126 44 0.73
135 48 0.96
108 42 0.88
TBI-7 M 75 ICH 9 9 2 Craniectomy 104 21 0.13
93 20 0.35
111 28 0.26
TBI-8 M 65 ICH, SDH 10 8 3 Craniectomy 89 16 0.20
Hemorrhagic stroke (HS)
HS-1 F 52 SAH, vasospasm
related infarction
15 8 3 Aneurysm clipping 119 27 0.12
HS-2 F 52 IVH, hydrocephalus 4 4 3 Hematoma evacuation ,
EVD
133 23 0.09
HS-3 M 36 SAH, ICH, IVH,
post-aneurysm
clipping infarction
13 8 3 Craniectomy, aneurysm
clipping
129 22 0.29
HS-4 M 38 ICH, IVH 6 6 3 EVD 117 20 0.13
132 16 0.73
Ischemic stroke (IS)
IS-1 F 64 Right ACA þ MCA 13 8 3 Craniectomy 88 34 0.41
93 39 0.03
IS-2 M 62 Left total MCA 11 11 3 Craniectomy 112 15 0.49
76 15 0.12
IS-3 F 62 Right ACA þ MCA 13 6 3 Craniectomy 84 19 0.56
86 20 0.78
IS-4 M 51 Right total MCA 11 6 1 Craniectomy 80 26 0.20
81 16 0.48
IS-5 F 84 Left total MCA 9 9 3 ICP monitor insertion 105 15 0.16
IS-6 F 61 Left total MCA 6 6 2 Craniectomy 113 21 0.62
101 34 0.34
Brain tumor (BT)
BT-1 F 28 Neurocytoma 15 15 2 Subtotal tumor excision,
craniectomy
169 33 0.21
78 31 0.85
BT-2 M 51 Meningioma 15 15 3 Subtotal tumor excision,
EVD
95 26 0.22
98 21 0.59
BT-3 F 53 Meningioma 15 15 5 Subtotal tumor excision –>
craniectomy with ICP
monitor
169 33 0.21
152 34 0.01
153 27 0.35
ACA Z anterior cerebral artery; EDH Z epidural hemorrhage; EVD Z extraventricular drainage; GCS Z Glasgow Coma Scale;
GOS Z Glasgow Outcome Scale (1 Z death; 5 Z low disability); ICP Z intracranial pressure; IVH Z intraventricular hemorrhage;
MABP Z mean arterial blood pressure; MCA Z middle cerebral artery; Preop Z preoperation; PRx Z pressure reactivity index;
SAH Z subarachnoid hemorrhage; SDH Z subdural hemorrhage.
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Figure 1 Before mannitol administration, baseline pressure
reactivity index was correlated significantly with levels of ICP
(p Z 0.0044, r Z 0.46).
846 S.-C. Tang et al.In the present study, the ability of CVPR, represented as
PRx in patients with increased ICP was usually impaired,
and the values of PRx were inversely correlated with the
level of ICP at baseline, which was consistent with previous
studies.19e24 Through monitoring of ABP and ICP during the
1-hour treatment course, our study further showed that
mannitol administration significantly decreased ICP and
consequently increased CPP in most events. However, the
responses of CVPR to mannitol treatment were diverse, in
that in around half of events, improvement was seen in
CVPR after treatment. Furthermore, quantitative analysis
of PRx showed that a higher baseline CPP was more likely to
lead to improvement of CVPR following mannitol adminis-
tration. The results of our study suggest that mannitol
might be administered to patients with increased ICP,
particularly for those with inadequate CPP. By contrast,
mannitol might not be empirically administered to patients
with already adequate or more than adequate CPP.
Under physiologic conditions, CA maintains a constant
cerebral blood flow despite fluctuations within a certain
range of CPP. However, the ability of CA may be impaired in
some pathologic conditions, rendering the patients
vulnerable to either cerebral ischemia or hyperperfusion
injury under low or high values of CPP. Therefore, in recent
decades, maintaining adequate CPP remains a cornerstone
of neurocritical care management,18 and CPP guidelinesTable 2 Variables measured before and after mannitol adminis
Baseline 0e10 min
Mean  SD
End reco
Mean  SD
MABP (mm Hg) 109.5  24.2 107.7  24
ICP (mmHg)b 26.0  9.1 23.1  8.4
CPP (mmHg) 83.5  23.0 84.6  23
PRx 0.31  0.39. 0.27  0.3
* p Z 0.036.
CPPZ cerebral perfusion pressure; ICPZ intracranial pressure; MABP
a Percentage change compared to the baseline values.
b Maximal ICP lowering effect indicated the lowest ICP after mann
minute).
c PRx was obtained every 10 minutes.have been included in care algorithms for traumatic brain
injury and stroke.1,15,16
After the introduction of the PRx method, several
studies have demonstrated the U-shape curve relationship
between the PRx and CPP in patients with head injury and
stroke.23,30,31 These clinical data were consistent with the
concept of CA that inadequate CPP and excessive CPP are
both associated with impairment of CVPR, theoretically.
Based on our data, we also showed that using mannitol to
reduce ICP in some patients with already high CPP might
further lead to even higher CPP, and possibly worsen CVPR.
In that situation, mannitol might not be used simply aiming
in reducing ICP levels, since its use may cause the afore-
mentioned medical complications instead.6,29
In addition, our study demonstrated the feasibility of
continuous monitoring of PRx in evaluating the effect of
mannitol administration on CVPR, especially in defining
patients who might have a deteriorated response of CVPR
after mannitol treatment. This could help to specifically
select patients who might benefit from mannitol treatment
not only in the degree of ICP lowering but in terms of the
status of CVPR. Reviewing the literature, only one article
mentioned PRx and mannitol treatment.32 That study
mainly focused on the change in regional cerebral oxygen-
ation following mannitol therapy and simply stated that PRx
did not change after treatment, which is in accordance
with our data, but no further subgroup data analysis and
correlation assay were performed, as was carried out in this
study.
There are some limitations of this study. First, the dis-
ease entity was not uniform and some patients had more
than one sampling event. Although most recruited patients
and study events (both >80%) were TBI and stroke in our
study and subgroup analysis did not show any difference in
baseline or response to mannitol treatment between these
two diseases, the heterogeneous patient groups might still
affect the results. Therefore, our study limited fewer than
three recording events in each study participants to lessen
the possible overweighting effect from a single participant.
Importantly, the results showed the same or with similar
trend if we chose the first measurement of each patient
into analysis. Second, it is possible that linear correlation
analysis of different time points of PRx may not reflect the
real physiological state of mannitol effect on CVPR. Intration in 21 patients with 37 recordings.
rding 50e60 min Maximal ICP lowering effect
34.4  12.4 min
%a Mean  SD %a
.9 1.7 107.1 23.7 0.7
11.2 21.2  11.1 19.2 *
.6 1.3 85.9  23.7 5.3
7. 12.3 Not availablec
Zmean arterial blood pressure; PRxZ pressure reactivity index.
itol administration (data of MABP, ICP, and CPP were averaged/
Figure 2 (A) The mean values of pressure reactivity index
did not change significantly during the course of mannitol
administration, but the individual response of cerebrovascular
pressure reactivity to mannitol treatment was diverse. Data
from two representative events demonstrated (B) a negative
slope and (C) a positive slope of linear correlations in the
change of pressure reactivity index, despite intracranial pres-
sure lowering during the course of treatment.
Mannitol and CVPR in ICP patients 847recent years, the clinical application of quantitative anal-
ysis of CVPR via PRx method has been demonstrated in a
number of studies focusing on TBI and stroke
patients.19e23,28e32 Therefore, we believe that the data of
the PRx changes during the 1-hour course of mannitol
treatment can be directly interpreted as the changes of
status of CVPR. Third, some concomitant medications that
possibly affect the status of CA, such as intravenous ste-
roid, were not evaluated in our study. Finally, the casenumber in our study is small, though the analytic result is
statistically significant. Further studies with larger sample
sizes and specific disease entity are necessary to strengthen
our findings and even offer a cut-off high CPP value not
suitable for routine mannitol administration. Nevertheless,
our study did bring out the important issue that assessment
of CVPR may help identify patients who get benefit from
mannitol. This is a good step forward from empirical
treatment to individual treatment.
In conclusion, the results of our study demonstrate the
possible diverse effects of mannitol on CVPR in patients
with increased ICP. Our study suggests that mannitol might
have beneficial effects on CVPR particularly in those with a
low CPP at baseline. Our study also emphasized the use-
fulness of multi-modal monitoring in assessment of CVPR in
the neurointensive care system.
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